Clinical Trials Logo
  1. Home
  2. Neuromuscular Disease
  3. NCT02288299

Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease — LIAM  

Neuromuscular Disease Clinical Trial

Official title:
Long-Term Effect of LIAM (Lung Insufflation Assist Maneuver) on Respiratory Performance in Non-invasive Ventilated Patients Suffering From Neuromuscular Disease

Clinical Trial Summary

The long-term effect of LIAM (Lung Insufflation Assist Maneuver) on respiratory performance in home non-invasively ventilated (NIV) patients suffering from neuromuscular disease will be assessed in a prospective, randomized, cross over, open label study

Clinical Trial Description

In advanced neuromuscular disorders, respiratory complications represent the main cause of morbidity and mortality. Beside chronic respiratory insufficiency, necessitating a ventilatory support, mostly performed by non-invasive ventilation (NIV), cough is impaired due to the muscle weakness, and respiratory physiotherapy becomes an essential part of the management.

Various techniques have been proposed to improve lung recruitment and cough in neuromuscular patients. The assisted techniques based on a positive pressure insufflation maneuver have shown an improvement in physiological variables on the short term, but there is to date no good-quality prospective study allowing to evaluate the long term efficacy of mechanical cough assistance devices in neuromuscular patients.

We designed a randomized, cross over, open label study to assess the long-term effect of LIAM (Lung Insufflation Assist Maneuver) on respiratory performance in NIV patients suffering from neuromuscular disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02288299
Study type Interventional
Source Centre d'Investigation Clinique et Technologique 805
Contact David Orlikowski, MD, PhD
Phone +33(0)147107777
Email david.orlikowski@rpc.aphp.fr
Status Recruiting
Phase N/A
Start date October 29, 2015
Completion date December 31, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02847299 - Comparison of a Hyperinflation Mode and Air Stacking on Neuromuscular Patients Under Volumetric Ventilation N/A
Completed NCT02551406 - Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients N/A
Completed NCT00860951 - P300 Brain Computer Interface Keyboard to Operate Assistive Technology Phase 1/Phase 2
Completed NCT02284022 - Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders. N/A
Completed NCT00001201 - Evaluation of Neuromuscular Disease N/A
Completed NCT00252252 - AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation Phase 1
Completed NCT02153970 - Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
Terminated NCT02317042 - Juno Perth Clinical Trial N/A
Terminated NCT02022072 - Evaluation of Vital Capacity Phase 2
Recruiting NCT04417023 - B3 for NMD: Bench to Bedside and Back
Recruiting NCT02532244 - Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
Completed NCT01621984 - Therapeutic Riding and Neuromuscular Disease Phase 1
Recruiting NCT01900132 - Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers N/A
Completed NCT00017745 - Phenotype/Genotype Correlations in Neuromuscular Disorders N/A
Recruiting NCT01560741 - Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation Phase 1
Completed NCT01644162 - Ventilator Monitoring in Early Exacerbation Detection N/A
Completed NCT00695591 - Home Sleep Testing in Neuromuscular Disease Patients N/A
Completed NCT01611597 - Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients N/A
Completed NCT01518439 - Instrumental and Manual Increase of Couch in Neuromuscular Patients N/A
Completed NCT01371149 - Patient -Ventilator Interaction in Chronic Respiratory Failure Phase 2